SOUTHWEST ONCOLOGY GROUP PHASE II TRIAL (S0341) OF ERLOTINIB (OSI-774) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AND A PERFORMANCE STATUS OF 2

PURPOSE: This phase II study (S0341) evaluated the efficacy and tolerability of single-agent erlotinib in unselected chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Exploratory analyses of a number of biomarkers relating to EGFR pathwa...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hesketh, Paul J., Chansky, Kari, Wozniak, Antoinette J., Hirsch, Fred R., Spreafico, Anna, Moon, James, Mack, Philip C., Marchello, Benjamin T., Franklin, Wilbur A., Crowley, John J., Gandara, David R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523698/
https://ncbi.nlm.nih.gov/pubmed/18758306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318183aa1f
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky